Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
Volume: 373, Issue: 17, Pages: 1627 - 1639
Published: Oct 22, 2015
Abstract
Nivolumab, a fully human IgG4 programmed death 1 (PD-1) immune-checkpoint–inhibitor antibody, disrupts PD-1–mediated signaling and may restore antitumor...
Paper Details
Title
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
Published Date
Oct 22, 2015
Volume
373
Issue
17
Pages
1627 - 1639
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History